Down the Pike

Chris at R&D Directions Insider blog spoke with both Merck's Alan Sachs and Amgen's Sean Harper down at the BIO meeting in Atlanta. Sachs is a VP of RNA Therapeutics and tells Chris that Merck isn't focusing on the delivery of RNA-based drugs but instead is looking whether RNA-based drugs make be safely taken for a chronic condition.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.